Merck Sharp & Dohme LLC has identified orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia and narcolepsy. BioWorld Science Neurology/psychiatric Patents Popular ...

W. Joseph Herring, MD, PhD, from Merck Sharp & Dohme in Whitehouse Station, NJ, and colleagues randomly assigned 254 healthy adults with primary insomnia to placebo or suvorexant (10mg, 20mg, 40mg ...

Committee members deem newly developed selective antagonist of orexin receptors effective but expressed concern about somnolence and driving safety for higher doses. ... Merck Sharp & Dohme Corp.) ...